Plain-English translation of NCT05082259 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination of two drugs: and . The goal is to see if giving these medications together can help people with advanced cancers that have stopped responding to standard treatments. The researchers believe this combination may help your immune system recognize and fight cancer cells more effectively.
Some advanced cancers stop responding to current immunotherapy treatments, leaving patients with few options. This trial is exploring whether adding this medication to an existing immune-boosting drug might work for people whose cancers have become resistant to other approaches.
You would take the first medication () by mouth for 7 consecutive days, then have a 14-day break, and repeat this cycle. You would receive the second medication () as an infusion every 3 weeks. Each treatment cycle lasts 21 days, and you would continue treatment as long as the medication appears to be helping and you're tolerating it well. You'll have regular visits with the research team for blood tests, scans, and check-ups to monitor how you're responding.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United Kingdom